Condition: Corneal Melting in Boston Keratoprosthesis Type I · Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
The purpose of this study is to demonstrate the safety and efficacy of the corneal collagen crosslinking with riboflavin and ultraviolet A in aim to increase the resistance of the graft used as a support for the Boston keratoprosthesis (KPro) type I against corneal melting (keratolysis or sterile necrosis).
This description comes directly from the study's public registry record.
Marie-Catherine Tessier · 514-890-8000 · marie-catherine.tessier.chum@ssss.gouv.qc.ca
Soumaya Bouhout · 514-264-0436 · soumiya.bouhout@gmail.com
Always discuss trial participation with your own doctor first.
| Centre Hospitalier de l'Université de Montréal | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03041883